10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks ad

10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Bioscien

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences PR Newswire PLEASANTON, Cali

Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidi

Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity chall

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Atera could meaningfully boost instrument sales in late 2026 and drive recurring high-margin consuma

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

First Trust Advisors LP bought a new stake in 10x Genomics (NASDAQ: TXG) during the first quarter, a

Stephens & Co. analyst Mason Carrico maintains 10x Genomics (NASDAQ:TXG) with a Overweight an

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and rai

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises t

Citigroup analyst Brendan Digan maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the

TXG beats Q2 earnings and revenue estimates, expands gross margin and raises its 2026 revenue outloo

10x Genomics NASDAQ: TXG reported second-quarter revenue of $151 million, including $1.6 million in

Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and r

10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in th

10x Genomics (TXG) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Esti

10x Genomics (NASDAQ:TXG) raises FY2026 sales outlook from $600.000 million-$625.000 million to $610

10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.14) per share which beat the analyst cons

PLEASANTON, Calif., Aug. 6, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science

10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings

This collaboration builds on 10x's broader efforts to work with leading research institutions to

Collaboration aims to identify biomarkers predictive of treatment response across multiple cancer ty

Tema's new Healthcare AI ETF (HLTH), targets AI-powered drug discovery, diagnostics, robotics an

Amova Asset Management Americas Inc. cut its holdings in shares of 10x Genomics (NASDAQ: TXG) by 7.0

Leerink Partners analyst Mike Kratky maintains 10x Genomics (NASDAQ:TXG) with a Market Perform an

Mitesco (OTCMKTS:MITI - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both m

PLEASANTON, Calif., July 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science

Warning: RSI is above 70 for 3 overbought stocks in healthcare. Progyny, 10X Genomics, and Privia He

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises t

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and r

Citigroup analyst Patrick Donnelly maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises

Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and rai

Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and raises th

TXG collaborates with the Cleveland Clinic to advance bladder cancer diagnostics using Flex Apex, Xe

Meeting marks formal transition of Andrew Snowden into role of President and CEO Toronto, Ontario--(

Torex Gold Resources Inc. (TXG:CA) Shareholder/Analyst Call Prepared Remarks Transcript

10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science

Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment resp

10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science

Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Equal-Weight and r

JP Morgan analyst Casey Woodring maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises th

10x Genomics (NASDAQ:TXG) affirms FY2026 sales outlook from $600.000 million-$625.000 million to $60

10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.10) per share which beat the analyst cons

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises t